Drug intelligence / Profile preview

SR11254

Development stage: Unknown
Modality: Small Molecules

Overview

SR11254 is an experimental small molecule that acts as a selective inhibitor of the retinoic acid receptor gamma (RARγ). It belongs to the class of naphthalenecarboxylic acids and has been studied for its ability to modulate gene expression by interfering with RARγ-mediated signaling. The compound binds to RARγ and inhibits its activity; this nuclear receptor normally regulates gene transcription in response to retinoic acid ligands. SR11254 has been used primarily as a research tool for studying the function and selectivity of RARγ in biological systems[1][4][9].

Other names: 6-((1Z)-(hydroxyimino)(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)methyl)naphthalene-2-carboxylic acid6-[HYDROXYIMINO-(5,5,8,8-TETRAMETHYL-5,6,7,8-TETRAHYDRO-NAPHTALEN-2-YL)-METHYL]-NAPHTHALENE-2-CARBOXYLIC ACID

Targets

RARG (Retinoic acid receptor gamma)

Beyond the preview

Go deeper on SR11254.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SR11254.

Explore the full profile